Sunshine Biopharma (SBFM) stock price, revenue, and financials

Sunshine Biopharma market cap is $5.5 m, and annual revenue was $21.12 k in FY 2019

$5.5 M

SBFM Mkt cap, 22-Sept-2020

$15.1 K

Sunshine Biopharma Revenue Q2, 2020
Sunshine Biopharma Gross profit (Q2, 2020)10 K
Sunshine Biopharma Gross profit margin (Q2, 2020), %65.9%
Sunshine Biopharma Net income (Q2, 2020)-907 K
Sunshine Biopharma EBIT (Q2, 2020)-128.6 K
Sunshine Biopharma Cash, 30-Jun-202085.6 K
Sunshine Biopharma EV5.9 M

Sunshine Biopharma Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

1.7k447.2k21.1k

Cost of goods sold

391.1k11.1k

Gross profit

56.1k10.1k

Gross profit Margin, %

13%48%

Sales and marketing expense

140.5k105.0k

R&D expense

142.7k1.8k137.4k327.0k8.7k32.8k12.8k15.2k

General and administrative expense

556.2k706.7k1.9m1.8m782.0k993.1k857.2k1.2m651.7k

Operating expense total

839.4k708.5k2.1m2.2m790.6k1.0m857.2k1.2m651.7k

Depreciation and amortization

4.3k60.7k6.6k2.4k13.8k

EBIT

(706.7k)(1.9m)(1.8m)(780.3k)(993.1k)(857.2k)(1.2m)(641.6k)

EBIT margin, %

(45684%)(261%)(3038%)

Interest expense

1.3k6.5k2.5m183.0k989.6k

Interest income

1.4k

Pre tax profit

(1.1m)

Net Income

(556.2k)(708.0k)(2.5m)(1.9m)(1.7m)(3.5m)(1.0m)(2.2m)(1.7m)

Quarterly

USDQ1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.7k91.2k107.3k136.9k119.7k3.0k7.3k11.1k15.1k

Cost of goods sold

91.6k102.8k84.9k1.5k5.3k3.9k5.2k

Gross profit

15.6k34.1k34.9k1.6k2.0k7.2k10.0k

Gross profit Margin, %

15%25%29%52%28%65%66%

Sales and marketing expense

15.1k100.0k

R&D expense

17.7k1.8k23.4k23.4k23.4k96.0k323.0k8.7k32.8k15.2k

General and administrative expense

49.2k16.5k116.4k39.3k102.7k376.4k922.9k1.1m1.3m405.9k765.5k277.4k124.8k369.9k113.1k69.7k382.3k116.0k109.0k472.2k113.8k257.9k586.6k313.9k155.7k67.8k204.7k44.9k138.6k

Operating expense total

82.0k16.5k116.4k39.3k104.5k376.4k946.3k1.1m1.3m501.9k1.2m277.4k124.8k369.9k121.7k69.7k415.1k116.0k109.0k472.2k113.8k257.9k586.6k313.9k155.7k67.8k204.7k44.9k138.6k

EBIT

(39.3k)(102.7k)(376.4k)(922.9k)(1.1m)(1.3m)(405.9k)(765.5k)(277.4k)(124.8k)(368.2k)(113.1k)(69.7k)(382.3k)(116.0k)(109.0k)(472.2k)(113.8k)(166.7k)(571.0k)(279.8k)(120.8k)(66.2k)(202.6k)(37.7k)(128.6k)

EBIT margin, %

(21555%)(183%)(532%)(204%)(101%)(2183%)(2766%)(340%)(849%)

Interest expense

16.0375.0375.05.3k5.7k6.1k95.4k52.9k3.4k169.5k33.2k9.8k7.0k10.0k12.1k9.1k9.6k27.4k75.5k28.4k24.3k49.8k18.3k27.8k16.4k24.2k

Pre tax profit

(350.2k)(94.3k)(907.4k)

Net Income

(49.2k)(16.5k)(116.4k)(39.3k)(103.1k)(376.8k)(1.5m)(1.6m)(1.8m)(501.3k)(818.4k)(280.8k)(294.4k)(517.5k)(202.8k)(305.3k)(392.3k)(1.6m)(195.7k)(485.4k)(147.6k)(265.6k)(644.3k)(907.6k)(202.5k)(710.9k)(350.2k)(95.6k)(907.0k)

Sunshine Biopharma Balance Sheet

Quarterly

USDQ1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

118.1k101.2k178.5k38.4k63.2k255.4k255.9k156.6k71.0k70.5k38.4k173.9k148.7k157.2k125.2k123.3k73.9k21.8k17.1k128.8k188.1k104.8k36.4k46.4k95.1k37.3k82.0k10.8k85.6k

Accounts Receivable

1.9k103.2k77.0k1.0k92.4k108.2k102.9k119.2k1.0k

Prepaid Expenses

41.3k41.3k45.7k45.7k45.7k12.6k3.0k4.2k617.01.3k5.6k6.4k11.6k11.4k846.08.5k9.8k5.3k1.1k1.2k3.7k6.8k3.2k1.9k2.4k

Inventories

13.2k18.2k17.8k13.7k16.6k

Current Assets

159.3k142.5k224.2k84.2k109.0k268.0k259.0k160.8k71.6k71.8k44.1k180.3k148.7k170.7k136.6k226.5k150.9k22.8k18.0k137.3k197.9k202.5k196.7k150.5k231.3k70.9k110.5k34.0k112.2k

PP&E

4.1k6.1k5.8k5.4k27.0k58.1k118.4k299.9k280.2k254.3k38.5k35.8k29.7k26.4k

Goodwill

673.6k673.6k673.6k665.7k

Total Assets

159.3k142.5k224.2k84.2k109.0k268.0k259.0k160.8k71.6k71.8k44.1k180.3k148.7k170.7k136.6k830.6k742.4k599.3k23.4k164.3k256.0k1.0m1.2m1.1m1.2m109.4k146.3k63.7k138.5k

Accounts Payable

330.04.5k8.0k16.5k1.6k8.3k293.08.8k49.5k93.9k51.3k46.6k35.7k34.6k24.5k35.7k19.3k28.0k34.7k12.1k113.4k139.0k105.0k140.3k84.4k64.8k98.0k89.9k

Short-term debt

12.5k12.5k12.5k12.5k12.5k12.5k132.5k282.5k396.0k313.1k390.6k418.6k269.1k324.1k249.0k71.4k213.4k391.6k785.1k719.7k361.1k745.4k747.9k721.8k674.3k357.3k

Current Liabilities

469.6k1.2m1.2m276.7k284.5k780.6k609.9k1.2m1.1m747.1k1.1m925.7k889.2k772.3k602.5k

Long-term debt

49.1k63.2k

Non-Current Liabilities

339.0k

Total Debt

12.5k12.5k12.5k12.5k12.5k12.5k132.5k282.5k396.0k313.1k390.6k418.6k269.1k324.1k498.0k71.4k426.7k391.6k1.6m1.4m722.1k1.5m1.4m1.3m674.3k502.7k

Total Liabilities

330.04.5k20.5k29.4k14.9k22.4k14.7k23.5k185.0k382.3k456.6k379.2k436.1k469.6k1.2m1.2m276.7k284.5k780.6k609.9k1.5m1.4m1.1m1.5m925.7k889.2k772.3k665.8k

Common Stock

30.7k30.7k31.0k48.7k49.2k51.4k56.2k56.4k56.4k62.7k66.0k68.9k102.4k126.5k134.4k232.9k274.4k636.0k817.9k868.6k918.7k948.0k1.1m1.6m89.3k104.3k311.4k59.7k269.8k

Preferred Stock

73.0k73.0k73.0k

Additional Paid-in Capital

1.8m1.8m2.0m2.3m2.5m3.0m4.7m4.7m4.8m5.8m6.4m6.7m7.4m7.8m7.9m8.8m9.0m11.1m11.6m11.7m12.1m12.4m13.1m13.8m15.6m15.7m15.9m16.7m17.5m

Retained Earnings

(1.8m)(1.8m)(1.9m)(2.3m)(2.4m)(2.8m)(4.5m)(4.6m)(4.8m)(6.0m)(6.8m)(7.1m)(7.7m)(8.2m)(8.4m)(9.4m)(9.8m)(11.5m)(12.8m)(13.3m)(13.4m)(13.9m)(14.5m)(15.4m)(16.0m)(16.7m)(17.0m)(17.5m)(18.4m)

Total Equity

159.3k142.5k219.7k63.7k79.6k253.2k236.6k146.1k48.1k(113.2k)(338.2k)(276.4k)(230.5k)(265.3k)(332.9k)(355.4k)(471.4k)322.6k(261.0k)(616.3k)(353.9k)(500.7k)(276.1k)44.7k(211.8k)(816.3k)(742.9k)(708.6k)(527.3k)

Debt to Equity Ratio

0.2 x0.2 x0 x0.1 x0.1 x0.3 x-1.2 x-0.8 x-1.4 x-1.4 x-1.5 x-1.3 x-0.8 x-0.7 x1.5 x-0.3 x-0.7 x-1.1 x-3.1 x-5.2 x16.2 x-7 x-1.7 x-1.8 x-1 x

Debt to Assets Ratio

0.1 x0.1 x0 x0 x0.1 x0.2 x1.8 x6.4 x2.2 x2.1 x2.3 x3.1 x0.3 x0.4 x0.8 x3.1 x2.6 x1.5 x1.6 x1.2 x0.7 x1.2 x12.6 x9.1 x3.6 x

Financial Leverage

1 x1 x1 x1.3 x1.4 x1.1 x1.1 x1.1 x1.5 x-0.6 x-0.1 x-0.7 x-0.6 x-0.6 x-0.4 x-2.3 x-1.6 x1.9 x-0.1 x-0.3 x-0.7 x-2 x-4.2 x24.7 x-5.9 x-0.1 x-0.2 x-0.1 x-0.3 x

Sunshine Biopharma Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(556.2k)(708.0k)(2.5m)(1.9m)(1.7m)(3.5m)(1.0m)(2.2m)(1.7m)

Depreciation and Amortization

4.3k60.7k6.6k49.4k13.8k

Accounts Receivable

15.4k(430.0)

Inventories

(15.9k)

Accounts Payable

(8.0k)(2.8k)23.2k11.0k11.8k(19.0k)(8.8k)61.6k(18.7k)

Cash From Operating Activities

(297.3k)(393.1k)(564.4k)(538.6k)(867.6k)(314.2k)(543.5k)(512.8k)(495.8k)

Purchases of PP&E

(4.8k)(3.4k)(3.7k)(18.8k)(860.0)

Cash From Investing Activities

(623.6k)(3.4k)(84.0k)(13.9k)(15.3k)

Short-term Borrowings

113.2k(115.0k)(194.2k)(53.0k)

Cash From Financing Activities

195.6k465.0k463.0k650.8k1.4m324.6k670.7k527.6k442.3k

Net Change in Cash

(101.7k)71.9k(101.4k)112.2k(92.6k)7.0k43.2k926.0(68.8k)

Interest Paid

5.3k21.9k23.5k

Income Taxes Paid

Quarterly

USDQ1, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(49.2k)(184.1k)(39.3k)(142.4k)(519.2k)(1.5m)(1.6m)(1.8m)(501.3k)(1.3m)(1.6m)(294.4k)(811.9k)(1.0m)(305.3k)(697.6k)(2.4m)(195.7k)(681.1k)(828.8k)(265.6k)(909.9k)(1.8m)(202.5k)(913.4k)(1.3m)(94.3k)(1.0m)

Depreciation and Amortization

15.2k30.2k45.2k525.01.0k4.9k6.7k16.4k43.3k579.06.8k10.3k3.8k7.0k

Accounts Receivable

(1.9k)(12.9k)(28.7k)(23.4k)(24.2k)(1.0k)430.0430.0

Inventories

(13.2k)(18.2k)(17.8k)2.2k(666.0)

Accounts Payable

(11.1k)(6.9k)4.6k13.1k(1.8k)7.7k(302.0)8.2k25.7k70.1k27.5k11.8k901.0(129.0)(52.1k)(89.3k)(107.8k)(171.0)342.8k(16.3k)(11.4k)14.2k(5.4k)(53.4k)(31.4k)(52.5k)1.2k(3.6k)

Cash From Operating Activities

(44.3k)(179.5k)(34.8k)(59.9k)(220.3k)(339.7k)(439.0k)(524.7k)(90.8k)(272.8k)(350.9k)(113.0k)(417.9k)(523.7k)(81.6k)(220.0k)(283.0k)(108.0k)(185.8k)(334.0k)(168.5k)(292.9k)(396.8k)(234.0k)(280.0k)(368.0k)(31.0k)(113.0k)

Purchases of PP&E

(2.3k)(2.3k)(22.3k)(4.8k)(27.4k)(27.4k)(485.0)

Cash From Investing Activities

(2.3k)(2.3k)(22.3k)(80.1k)(22.4k)(22.4k)(13.0k)(14.4k)

Short-term Borrowings

(5.1k)(5.1k)75.0k75.0k166.2k(50.0k)(130.9k)(146.2k)(146.2k)(53.8k)(53.0k)(53.0k)

Cash From Financing Activities

195.6k12.5k62.5k415.0k463.0k463.0k463.0k130.0k280.0k493.5k118.3k431.7k505.5k164.1k244.1k255.3k66.2k275.7k456.5k248.6k250.0k354.9k214.7k219.4k352.1k159.0k

Net Change in Cash

(44.3k)16.1k(22.3k)2.6k194.7k123.3k24.0k(61.7k)39.2k7.2k142.6k5.3k13.8k(18.2k)82.5k21.8k(30.0k)(41.8k)67.5k122.5k(31.0)(65.4k)(64.3k)(19.3k)(75.0k)(30.3k)(31.0k)46.0k

Interest Paid

40.0k3.5k9.4k13.6k13.6k11.0k11.0k11.0k

Income Taxes Paid

Sunshine Biopharma Ratios

USDQ1, 2011

Financial Leverage

1 x